NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting
21 mars 2023 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in...
Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
14 mars 2023 07h05 HE
|
Virios Therapeutics
ATLANTA, March 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
Anticonvulsant Drugs Market to Surpass US$ 8,030.4 Million by 2030, Says Coherent Market Insights (CMI)
22 févr. 2023 09h15 HE
|
CMI
Burlingame, Feb. 22, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global anticonvulsant drugs market is estimated to be valued at US$ 6,757.8 in 2022 and is expected to...
Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program
05 janv. 2023 07h00 HE
|
Virios Therapeutics
ATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat...
NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting
08 nov. 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on...
NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia
03 nov. 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the strategic launch of its Quell® Fibromyalgia device through the Pathfinder Program. Quell...
Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
20 sept. 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American...
NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia
19 mai 2022 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation...
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
22 mars 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
02 févr. 2022 16h05 HE
|
Exagen Inc.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health,...